Clay Siegall Leading Seattle Genetics and the Fight vs. Cancer

Seattle Genetics has made headlines as of late as a hot stock to buy, but the company itself is emerging in its own right in the biotech industry. Seattle Genetics develops and then commercializes cancer treatment utilizing their antibody-based therapeutic drugs.

Though not in Seattle itself, the company is located in the city’s suburbs in Bothell, Wash. It has become a leader in anti-cancer drugs as their design help monoclonal antibodies kill off cancer cells within a host. Its top product is Adcetris is used to help treat Hodgkin lymphoma.

Seattle Genetics also has gained approval of Brentuximab vedotin and is working another conjugate, SGN-CD19A.

Initially formed in 1997, the company went public in 2001. Since then, it has become a biotech leader with its drugs against cancer. In utilizing antibody drug conjugates (ADC) as its chief weapon against cancer, the company sought to find a way to protect non-cancerous cells and prevent side effects of its treatments that are commonly found in chemotherapy.

Adcetris has been used to help over 15,000 patients suffering some form of lymphoma. Seattle Genetics has as many as seven different programs in its clinical stage in hopes of finding a breakthrough that can help lead to a cure for cancer.

Leading to charge of Seattle Genetics, which now employees over 650 and has plans to add to its workforce, is its CEO and president Clay Siegall. He founded Seattle Genetics since its inception and has served as its chief since then, overseeing its rise toward the top of its industry.

Siegall earned a Bachelor of Science degree from the University of Maryland in the field of zoology and also a Ph.D in genetics from George Washington University, creating the basis of his knowledge and know-how in the field of biotech.

Siegall is also a member of a number of company boards such as Mirna Therapeutics and Ultragenyx Pharmaceutical as well as Seattle Genetics.

Start a Conversation

Your email address will not be published. Required fields are marked *